Actinium Pharmaceuticals/$ATNM
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Actinium Pharmaceuticals
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of targeted radiotherapies using its Antibody Radiation Conjugates (ARCs) platform, which combines monoclonal antibodies with radioisotopes to selectively target and destroy cancer cells. The company's product candidates include Iomab-B, an iodine-131 based radiotherapy for conditioning prior to hematopoietic stem cell transplantation, and Actimab-A, an actinium-225 based radiotherapy in clinical development for acute myeloid leukemia. The company is also advancing additional programs, including Iomab-ACT for cell and gene therapy conditioning and other preclinical candidates targeting solid tumors.
Ticker
$ATNM
Sector
Primary listing
AMEX
Employees
25
Headquarters
Website
ATNM Metrics
BasicAdvanced
$36m
-
-$0.76
-
-
Price and volume
Market cap
$36m
52-week high
$1.95
52-week low
$0.95
Average daily volume
220k
Financial strength
Current ratio
5.887
Quick ratio
5.733
Long term debt to equity
34.071
Total debt to equity
65.929
Profitability
EBITDA (TTM)
-25.347
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-26,078.89%
Operating margin (TTM)
-28,346.67%
Management effectiveness
Return on assets (TTM)
-27.95%
Return on equity (TTM)
-167.66%
Valuation
Price to revenue (TTM)
398.752
Price to book
15.66
Price to tangible book (TTM)
15.66
Price to free cash flow (TTM)
-1.562
Free cash flow yield (TTM)
-64.04%
Free cash flow per share (TTM)
-0.736
Growth
Earnings per share change (TTM)
-48.66%
3-year earnings per share growth (CAGR)
-21.36%
10-year earnings per share growth (CAGR)
-26.48%
What the Analysts think about ATNM
Analyst ratings (Buy, Hold, Sell) for Actinium Pharmaceuticals stock.
ATNM Financial Performance
Revenues and expenses
ATNM Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Actinium Pharmaceuticals stock?
Actinium Pharmaceuticals (ATNM) has a market cap of $36M as of May 20, 2026.
What is the P/E ratio for Actinium Pharmaceuticals stock?
The price to earnings (P/E) ratio for Actinium Pharmaceuticals (ATNM) stock is 0 as of May 20, 2026.
Does Actinium Pharmaceuticals stock pay dividends?
No, Actinium Pharmaceuticals (ATNM) stock does not pay dividends to its shareholders as of May 20, 2026.
When is the next Actinium Pharmaceuticals dividend payment date?
Actinium Pharmaceuticals (ATNM) stock does not pay dividends to its shareholders.
What is the beta indicator for Actinium Pharmaceuticals?
Actinium Pharmaceuticals (ATNM) does not currently have a Beta indicator.